Janet Gilbreath
Psychiatry · Nampa, IDNPI 1013024827
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 352 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 352 payments — averaging $24.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$816
- Neurocrine Biosciences, Inc.$766
- Johnson & Johnson$744
- Vanda Pharmaceuticals Inc.$630
- plus $3K from 17 others
What the payments were for
- Food & beverage$8,21395%
- Education$3895%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 117 | $1,999 |
| Teva Pharmaceuticals USA, Inc. | 44 | $1,086 |
| Otsuka America Pharmaceutical, Inc. | 35 | $816 |
| Neurocrine Biosciences, Inc. | 20 | $766 |
| Johnson & Johnson | 24 | $744 |
| Vanda Pharmaceuticals Inc. | 24 | $630 |
| E.r. Squibb & Sons, L.L.C. | 13 | $530 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $482 |
| Axsome Therapeutics, Inc. | 10 | $393 |
| Alkermes, Inc. | 7 | $300 |
| Eisai Inc. | 7 | $188 |
| Corium, LLC | 8 | $181 |
| Lundbeck LLC | 5 | $116 |
| Ironshore Pharmaceuticals Inc. | 3 | $65 |
| Janssen Scientific Affairs, LLC | 1 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Merck | 2 | $37 |
| Tris Pharma Inc | 2 | $34 |
| Indivior Inc. | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Sunovion Pharmaceuticals Inc. | 3 | $24 |
| Biogen | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$364
- VRAYLAR$351
- Fanapt$250
- ABILIFY ASIMTUFII$237
- ABILIFY MAINTENA$237
- VIVITROL$121
- CAPLYTA$120
- Auvelity$118
- INVEGA SUSTENNA$109
- SPRAVATO$107
- UBRELVY$107
- Dayvigo$104
How this compares
$8,601 in reported general payments places this provider in the 95th percentile of 98 psychiatry providers in Idaho.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 14 | $50,739 |
| CaplytaLumateperone Tosylate | 19 | $39,180 |
| Chlorpromazine Hcl | 12 | $34,038 |
| VraylarCariprazine Hcl | 17 | $23,519 |
| Paliperidone ErPaliperidone | 11 | $6,649 |
| DayvigoLemborexant | 13 | $4,167 |
| Aripiprazole | 22 | $3,604 |
| Gabapentin | 50 | $1,917 |
| Lamotrigine | 73 | $727 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $597 |
| Prazosin Hcl | 13 | $269 |
| Trazodone Hcl | 44 | $265 |
| Buspirone Hcl | 15 | $171 |
| Sertraline Hcl | 12 | $169 |
| Escitalopram Oxalate | 24 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $744 | $50,73914 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $482 | $39,18019 claims |
| AbbVieVraylar | $1,999 | $23,51917 claims |
| Eisai Inc.Dayvigo | $188 | $4,16713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 98 psychiatry providers in Idaho.
Other psychiatry in Nampa
- John NguyenNampa$77
- Craig DennyIdaho Falls$10K
- Linda CarterPocatello$9K
- Olurotimi AshayeMeridian$8K
- Thomas HolmesLewiston$8K
- Albert CrookCoeur D'alene$5K
- Richard PinesBoise$4K
- Cristina Sanchez JaquezAmmon$4K
- Lawrence BantaCaldwell$3K
- Zachary MorairtyTwin Falls$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.